Surgery Websites
Transplant Surgery »  Meet the Team »  Gastroenterology »  Jonathan P. Terdiman, M.D.
Jonathan P. Terdiman, M.D.

Jonathan P. Terdiman, M.D.

  • Professor of Clinical Medicine and Surgery
  • Chief, Clinical Gastroenterology
  • Associate Director, Colitis and Crohn's Disease Center
  • Director, Hereditary Gastrointestinal Cancer Prevention Program

Contact Information

Academic Office
Division of Gastroenterology
2330 Post Street, Suite 610
San Francisco, CA 94115
Phone: (415) 353-7906
Fax: 415-502-2249
[email protected]		 Gastroenterology at Mount Zion
2330 Post St., Suite 610
San Francisco, CA 94115
Phone: (415) 502-4444
Fax: (415) 502-2249
Hours: Monday to Friday
9 a.m. - 4:30 p.m.
Inflammatory Bowel Disease Center
2330 Post St., Sixth Floor
San Francisco, CA 94115
Phone: (415) 502-4444
Fax: (415) 502-2249

Cancer Risk Program
1600 Divisadero St., Second Floor
San Francisco, CA 94143-1714
Phone: (415) 885-7779
Open Popup

Education

1981-85 College, Princeton University, A.B., cum laude
1985-89 Medical School, Columbia University, College of Physicians and Surgeons, M.D

Residencies

  • 1989-1990 Internship, Internal Medicine, University of California, San Francisco
  • 1990-1992 Residency, Internal Medicine, University of California, San Francisco

Fellowships

  • 1992-1993 Fellowship, Critical Care Medicine, University of California, San Francisco
  • 1993-1996 Fellowship, Gastroenterology, University of California, San Francisc

Board Certifications

  • American Board of Internal Medicine, Diplomate in Internal Medicine
  • American Board of Internal Medicine, Diplomate in Gastroenterology

Program Affiliations

  • UCSF Helen Diller Family Comprehensive Cancer Center
  • Division of Colorectal Surgery, Department of Surgery
  • Gastrointestinal Cancer Prevention Program
  • Colitis and Crohn's Disease Center

Clinical Expertise

Research Interests

  • Colorectal cancer prevention and risk identification
  • Prognostic and predictive biomarkers in IBD

Biography

Jonathan Terdiman, M.D. is co-director of the Center for Inflammatory Bowel Disease and the Colorectal Cancer Prevention Program at UCSF Medical Center. His research interests include colorectal cancer prevention, hereditary gastrointestinal cancer and inflammatory bowel disease. He frequently lectures in the community, at the university and for various professional organizations on these subjects.

Terdiman earned a medical degree at Columbia University, College of Physicians and Surgeons. He went on to complete a residency in internal medicine and fellowships in critical care medicine and gastroenterology at UCSF where he is a professor of clinical medicine and surgery.

Research Overview

Dr. Terdiman's research interests are related to clinical and translational research in the areas of colorectal cancer prevention, especially among individuals at high risk for cancer, such as those with hereditary cancer syndromes or those with longstanding inflammatory bowel disease. Particular areas of interest include the optimal provision of genetic counseling and testing, cancer risk factor
identification and risk mitigation by interventions such as drugs (chemoprevention) and colonoscopy. 

Dr. Terdiman also studies the use of genetic and genomic markers to determine cancer risk and prognosis and prediction of response to therapy among those already diagnosed with cancer. He also is interested in projects related to biomarkers of prognosis and prediction of response to therapies in patients with inflammatory bowel disease.

Clinical Trials

Data provided by UCSF Profiles, powered by CTSI

Publications

MOST RECENT PUBLICATIONS FROM A TOTAL OF 116
Data provided by UCSF Profiles, powered by CTSI
  1. Mennillo E, Kim YJ, Rusu I, Lee G, Dorman LC, Bernard-Vazquez F, Bain JL, Patel R, Andersen C, Rao A, Tamaki S, Tsui J, Shen A, Naser M, Eckalbar W, Cho SJ, Beck K, El-Nachef N, Lewin S, Selvig DR, Terdiman JP, Mahadevan U, Oh D, Fragiadakis GK, Pisco A, Combes A, Kattah MG. Single-cell and spatial multi-omics identify innate and stromal modules targeted by anti-integrin therapy in ulcerative colitis. bioRxiv. 2023 Jul 15. View in PubMed
  2. Chugh R, Braga-Neto MB, Fredrick TW, Ramos GP, Terdiman J, El-Nachef N, Loftus EV, Mahadevan U, Kane SV. Multicentre Real-world Experience of Upadacitinib in the Treatment of Crohn's Disease. J Crohns Colitis. 2023 Apr 19; 17(4):504-512. View in PubMed
  3. Wang CW, Mclean I R, Cheng YW, Kim S, Terdiman J, Kathpalia P, Beck KR. Racial Disparities in Endoscopy Cancellations During the COVID-19 Pandemic. Dig Dis Sci. 2023 03; 68(3):729-735. View in PubMed
  4. Smith BJ, Piceno Y, Zydek M, Zhang B, Syriani LA, Terdiman JP, Kassam Z, Ma A, Lynch SV, Pollard KS, El-Nachef N. Strain-resolved analysis in a randomized trial of antibiotic pretreatment and maintenance dose delivery mode with fecal microbiota transplant for ulcerative colitis. Sci Rep. 2022 04 01; 12(1):5517. View in PubMed
  5. Feuerstein JD, Ho EY, Shmidt E, Singh H, Falck-Ytter Y, Sultan S, Terdiman JP, American Gastroenterological Association Institute Clinical Guidelines Committee. AGA Clinical Practice Guidelines on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn's Disease. Gastroenterology. 2021 06; 160(7):2496-2508. View in PubMed
  6. View All Publications

 

 
Site Directory
    X